"Me-Too" Drug Pediatric Study Should Await Safety Data From Marketing
Executive Summary
"Me-too" drugs could be required to include statements recommending use of competitor drugs as part of the "pediatric use" section of labeling, FDA's final pediatric rule indicates.
You may also be interested in...
Pediatric Waivers Contingent On Study Attempts In Sub-Populations - FDA
Sponsors may have to attempt pediatric studies in small patient populations before FDA grants a pediatric waiver, FDA suggests in a list of "Frequently Asked Questions on Pediatric Exclusivity (505A), The Pediatric 'Rule,' and Their Interaction" posted on its website July 27.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011